Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
CYTK Stock Chart & Stats
$63.36
-$0.99(-2.05%)
At close: 4:00 PM EST
$63.36
-$0.99(-2.05%)
Day’s Range― - ―
52-Week Range$29.31 - $70.98
Previous CloseN/A
Volume107.14K
Average Volume (3M)1.65M
Market Cap
$7.62B
Enterprise Value$8.69B
Total Cash (Recent Filing)$962.53M
Total Debt (Recent Filing)$1.20B
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Mar 04, 2026EPS Estimate
-1.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.55
Shares Outstanding122,264,930
10 Day Avg. Volume1,610,781
30 Day Avg. Volume1,648,917
Financial Highlights & Ratios
PEG Ratio2.56
Price to Book (P/B)-38.91
Price to Sales (P/S)285.13
P/FCF Ratio-13.18
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue99.64
Enterprise Value/Gross Profit-78.13
Enterprise Value/Ebitda-13.45
Forecast
1Y Price Target
$91.71Price Target Upside44.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial UpsidePositive topline results from the late‑stage ACACIA‑HCM trial would validate broader efficacy across the hypertrophic cardiomyopathy spectrum and could meaningfully expand the addressable market and investor confidence.
Commercial Launch ReadinessEstablished commercial and medical affairs teams combined with planned disclosure of prescriber and prescription metrics signal launch preparedness that could accelerate capture of treatment‑naive patients and early market share.
Regulatory ApprovalFDA approval of MYQORZO with a differentiated label and a streamlined REMS that reduces echocardiogram requirements and simplifies monitoring could make the therapy more attractive to prescribers compared with the incumbent.
Bears Say
Commercial Execution RiskMarket sentiment is likely to remain muted because the investment thesis depends on flawless commercial execution and trial validation, so execution missteps could constrain upside.
Incumbent CompetitionStrong sales and launch momentum for Camzyos create a first‑mover advantage that may limit how much market share Myqorzo can capture in the near term.
Payer Access And PricingAchieving payer access parity with the incumbent is uncertain, and delays or tougher coverage decisions could temper revenue expectations and slow patient switching.
Cytokinetics News
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $29.31 and its highest was $70.98 in the past 12 months.
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is $7.62B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Mar 04, 2026 which is in 22 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Nov 05, 2025. The company reported -$2.55 earnings per share for the quarter, missing the consensus estimate of -$1.571 by -$0.979.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.57.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 122,264,930 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$2.55 in its last earnings report, missing expectations of -$1.571. Following the earnings report the stock price went up 1.875%.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CYTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cytokinetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$91.71 (44.74% Upside)
$91.71 (44.74% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.03%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
CYTK Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress towards the approval and commercial readiness of aficamten, supported by strong clinical trial results and a solid financial position. However, increased net loss and pending regulatory approvals present challenges.View all CYTK earnings summariesCYTK Stock 12 Month Forecast
Average Price Target
$91.71
▲(44.74% Upside)
Technical Analysis
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Avidity Biosciences
―
Nuvalent
―
Ownership Overview
Currently, No data available
---